Last updated: February 24, 2026
What is NDC 42192-0331?
NDC 42192-0331 corresponds to Amgen’s biosimilar product. The exact drug name is Kanjinti (trastuzumab-anns), a biosimilar to Herceptin (trastuzumab), used primarily for HER2-positive breast cancer and gastric cancer. It entered the biosimilar market around 2019.
Market Landscape
Therapeutic Area and Demand
Kanjinti competes in the HER2-targeted cancer therapy segment, a multibillion-dollar market. The global trastuzumab market was valued at approximately $8.5 billion in 2021, with projections reaching over $11 billion by 2028[1].
- Key competitors: Herceptin (original), Herzuma, Ogivri, and Trazimera.
- Market growth drivers:
- Patent expiration of Herceptin in major markets starting 2018.
- Rising adoption of biosimilars to reduce treatment costs.
- Increasing incidence rates of breast and gastric cancers worldwide.
Revenue and Market Share
Since biosimilar entry:
- Kanjinti captured an estimated 10–15% share of trastuzumab sales in the U.S. by 2022.
- Overall biosimilar trastuzumab sales in the U.S. reached approximately $1.2 billion in 2022, growing at about 20% annually[2].
Geographic Penetration
- North America accounts for over 50% of sales.
- Europe exhibits significant adoption, driven by price competition and biosimilar policies.
- Emerging markets show slower adoption due to regulatory hurdles.
Price Projections
Current Pricing Dynamics
- U.S. retail price per 440 mg vial (average): $2,400 - $2,700.
- Estimated average wholesale price (AWP): approximately $2,600 per vial.
- Biosimilar discounts relative to Herceptin:
- Typically 15–20% lower retail pricing.
- Contract discounts and rebates significantly influence actual net prices.
Short-term Price Trends (Next 2 Years)
- Pricing pressure due to increased biosimilar competition will likely reduce prices by an additional 10–15% in 2023–2024.
- Market saturation and reimbursement policies may impact pricing, causing further price erosion in major markets.
Long-term Price Projections (2025-2030)
| Year |
Estimated Retail Price (per vial) |
Notes |
| 2025 |
$2,100 - $2,400 |
Continued price competition, growing biosimilar availability |
| 2027 |
$1,950 - $2,250 |
Potential market consolidation, value-based pricing initiatives |
| 2030 |
$1,800 - $2,100 |
Market stabilization; biosimilar price attrition plateau |
Prices could decline further in less regulated markets with rapid biosimilar entry and aggressive price competition.
Impact of Policy and Reimbursement
- US policies favor biosimilar substitution, leading to lower patient out-of-pocket costs[3].
- European countries actively promote biosimilar uptake, pressuring prices downward.
- Reimbursement policies may incentivize lower prices through formulary management.
Future Market Drivers and Risks
Drivers
- Increased clinician acceptance and patient access.
- Expanded indications for trastuzumab biosimilars.
- Contractual and policy incentives favoring biosimilars.
Risks
- Delays in biosimilar approval or market approval.
- Patent litigations and exclusivity rights.
- Regulatory hurdles in emerging markets.
Key Takeaways
- The biosimilar market for trastuzumab is dynamic, with strong growth since 2018.
- Kanjinti holds a moderate market share but faces intense competition.
- Prices are expected to decline gradually, with a potential 10–15% reduction by 2024.
- Long-term prices may stabilize around $1,800–$2,100 per vial fueled by increased biosimilar penetration and policy measures.
- Market expansion relies heavily on clinician acceptance, reimbursement policies, and regulatory environment.
FAQs
1. What are the key factors affecting the price of NDC 42192-0331?
Market competition, biosimilar penetration, insurance reimbursement policies, and regulatory approvals primarily influence pricing.
2. How does the competitive landscape influence future prices?
Increased biosimilar entry pushes prices downward, especially where regulatory and reimbursement frameworks favor substitution.
3. What regions will see the most significant price reduction?
Europe and North America will experience the steepest declines due to established biosimilar policies and market acceptance.
4. What role do rebates and discounts play in net pricing?
Rebates and negotiated discounts often reduce list prices by 20–30%, significantly impacting net revenues.
5. What is the outlook for biosimilar uptake in emerging markets?
Slower adoption due to regulatory hurdles and cost sensitivity limits immediate price declines, but growth is expected with policy shifts.
References
- MarketsandMarkets. (2023). Biosimilars Market by Type, Application, and Region - Global Forecast to 2028.
- IQVIA. (2023). Top Oncology Drugs and Market Trends.
- Food and Drug Administration. (2022). Biosimilars and Interchangeable Products Policy.
